Zydus Lifesciences Limited, in collaboration with the Indian Council of Medical Research (ICMR), has announced the successful completion of Phase II Proof-of-Concept trials and approval...
Novo Nordisk’s Etavopivat hits the mark in Pivotal Sickle Cell Study. Etavopivat, an oral, once-daily pyruvate kinase-R (PKR) activator displayed supercilious results showing 27%...